The U.S. Justice Department and the federal Environmental Protection Agency have reached an agreement with a Houston company on alleged violations of the federal Clean Air Act. Photo via Getty Images

Officials have reached an agreement with a Houston-based company over alleged violations of the federal Clean Air Act.

Under a proposed settlement with the U.S. Justice Department and the federal Environmental Protection Agency, Derichebourg Recycling USA Inc. will prevent the release of ozone-depleting refrigerants and non-exempt substitutes from refrigerant-containing items at its 10 scrap metal recycling facilities in Texas and Oklahoma. Derichebourg also will pay a $442,500 penalty.

Derichebourg Recycling USA’s parent company is France-based Derichebourg SA, an operator of scrap metal recycling facilities.

A complaint filed in federal court alleges Derichebourg Recycling USA failed to recover refrigerant from appliances and motor vehicle air conditioners before disposal, and failed to verify with the supplier that refrigerant had been properly recovered before delivery.

The complaint focuses on alleged Clean Air Act violations at three Derichebourg scrap metal recycling facilities in Houston: 7501 Wallisville Rd., 8202 W. Montgomery Rd., and 1 Wharf St. Environmental Protection Agency (EPA) inspections in 2018 led to the complaint.

Derichebourg operates three other facilities in the Houston area: 3515 Almeda Genoa Rd. and 6648 N. Eldridge Pkwy., both in Houston, and 13319 FM 1764 in Santa Fe.

“To continue protecting stratospheric ozone, we need companies like Derichebourg to comply with the Clean Air Act when recycling appliances and motor vehicles containing harmful refrigerants,” Todd Kim, an assistant U.S. attorney general, says in a January 7 news release.

The refrigerant, R-12, is one of the most destructive ozone-depleting substances and has a global warming potential greater than 10,000 times the power of carbon dioxide, according to the news release.

“Refrigerants that are not captured properly can be damaging to the earth’s ozone layer and are known to increase greenhouse gasses, which leads to climate change,” says Larry Starfield, acting assistant administrator of the EPA.

The agreement, called a consent decree, still requires approval from a federal judge in Houston. The consent decree is signed by two EPA attorneys and the CEO of Derichebourg Recycling USA, Philippe Leonard.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.